Cardiff Oncology (CRDF)

• Market cap: $134M
• 1 day: 0.5%
• 5 days: -1.47%
• 1 month: -17.28%
• 3 months: -45.68%
• 6 months: -50.37%
• Year to date: -52.82%
• 1 year: -20.87%
• 5 years: -75.22%
• 10 years: -99.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Employees: 33

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

203% more call options, than puts

Call options by funds: $3.65M | Put options by funds: $1.2M

96% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 23

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

3% less funds holding

Funds holding: 116 [Q1] → 113 (-3) [Q2]

5.6% less ownership

Funds ownership: 48.62% [Q1] → 43.03% (-5.6%) [Q2]

11% less capital invested

Capital invested by funds: $102M [Q1] → $90.2M (-$11.4M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3.5
• Avg. target: $10.83
• High target: $19

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

HC Wainwright & Co. Robert Burns	$10	Buy Maintained	6 Aug 2025
Ladenburg Thalmann Kevin DeGeeter	$19	Buy Initiated	8 Jul 2025
Jefferies Maury Raycroft	$3.5	Hold Initiated	24 Jun 2025